California Court Dismisses Sleep Tech Patent Suit Against ResMed: Key IP Strategy Insights
What would you like to do next?
Choose your path based on your current IP needs:
In a decisive ruling that closed the case without opportunity for amendment, the U.S. District Court for the Southern District of California granted ResMed Co.’s motion to dismiss the patent infringement complaint filed by Craig L. Linden—denying plaintiff any leave to amend. The case, Linden v. ResMed Co., No. 3:24-cv-01291, centered on U.S. Patent No. 9,639,150 B2, a technology patent asserted against a broad portfolio of ResMed’s flagship respiratory therapy devices, including the widely deployed AirSense 10, AirSense 11, AirCurve 10, and AirCurve 11 product families, as well as accompanying software platforms.
Filed in July 2024 and closed by February 2026, the litigation lasted approximately 579 days before terminating at the first-instance level. The outcome—a full dismissal without leave to amend—signals meaningful procedural and substantive vulnerabilities in the complaint and carries implications for patent holders asserting medical device patents, particularly in the competitive sleep therapy and respiratory care market.
For patent litigators, IP managers, and R&D teams operating in the medical device space, this case offers critical lessons about complaint sufficiency, patent assertion strategy, and defensive litigation by well-resourced defendants.
📋 Case Summary
| Case Name | Linden v. ResMed Co. |
| Case Number | 3:24-cv-01291 |
| Court | S.D. California (District Court) |
| Duration | July 2024 – Feb 2026 579 days |
| Outcome | Defendant Win — Dismissal without leave to amend |
| Patents at Issue | |
| Accused Products | AirSense 10/11, AirCurve 10/11, AirView, myAir |
Case Overview
The Parties
⚖️ Plaintiff
An individual patent holder asserting rights under U.S. Patent No. 9,639,150 B2.
🛡️ Defendant
A global leader in cloud-connected medical devices for sleep apnea, COPD, and other respiratory conditions.
Patents at Issue
This case centered on U.S. Patent No. 9,639,150 B2, a technology patent asserted against ResMed’s respiratory therapy devices. The patent likely pertains to adaptive or automated respiratory therapy control systems, a technology domain directly intersecting with ResMed’s servo-ventilation and bilevel pressure device capabilities.
- • US 9,639,150 B2 — Adaptive or automated respiratory therapy control systems.
Legal Representation
Plaintiff was represented by Ryan Benjamin Abbott and Ryan Ephraim Hatch of Brown, Neri, Smith & Khan LLP and Hatch Law PC—boutique firms with plaintiff-side IP litigation practices.
Defendant ResMed retained Paul Hastings, LLP, a global Am Law 100 firm with a formidable IP litigation defense practice, represented by Eric Edmund Lancaster, Joshua Yin, Kamilah Alexander, and Lisa K. Nguyen.
Litigation Timeline & Procedural History Highlights
The case was filed in the Southern District of California, a venue with established familiarity in technology and medical device patent disputes. The matter proceeded at the first-instance (district court) trial level and did not advance to claim construction, summary judgment, or trial before termination. The 579-day duration from filing to dismissal suggests the parties engaged in substantive motion practice before the court resolved the case on ResMed’s motion to dismiss—likely under Federal Rule of Civil Procedure 12(b)(6). The absence of leave to amend indicates the court found no viable path to a legally sufficient complaint.
Developing a new medical device?
Check if your sleep tech or respiratory device design might infringe existing patents before launch.
The Verdict & Legal Analysis
Outcome
The court granted ResMed’s motion to dismiss the complaint without leave to amend, directing the Clerk to close the case. No damages were awarded, and no injunctive relief was issued. The dismissal without leave to amend is a terminal disposition—more definitive than a typical dismissal with leave, and indicative of fundamental deficiencies the court found incurable.
Verdict Cause Analysis
The verdict cause is recorded as an Infringement Action—meaning the case was initiated as a standard patent infringement claim under 35 U.S.C. § 271. The dispositive outcome at the motion-to-dismiss stage typically implicates one or more of the following legal grounds:
1. Pleading Insufficiency Under Twombly/Iqbal: Post-Iqbal and Twombly, patent infringement complaints must contain plausible, specific factual allegations mapping asserted claims to accused products. Courts increasingly dismiss complaints that recite claim language without explaining how each accused product meets each claim limitation.
2. Patent Eligibility Under 35 U.S.C. § 101: In the medical device software space, § 101 Alice/Mayo challenges remain potent. If U.S. 9,639,150 B2 includes software-implemented or method claims directed to abstract data processing concepts without sufficient inventive application, a § 101 challenge at the pleading stage could support dismissal without amendment.
3. Claim Construction Implications: While formal Markman proceedings typically occur later in litigation, courts sometimes apply preliminary claim construction analysis at the motion-to-dismiss stage where claim scope is dispositive. A narrow claim construction could have eliminated infringement allegations as a matter of law.
The “without leave to amend” designation is particularly significant: it signals the court’s determination that amendment could not cure the complaint’s deficiencies—suggesting a substantive legal bar rather than a mere pleading technicality.
Legal Significance
This dismissal reinforces a critical post-Iqbal litigation reality: complaint quality is a first-line defense battlefield. For patent holders asserting complex medical device patents, particularly those covering software-hardware integrated systems across multiple product lines, robust claim charts and specific technical allegations are not optional—they are jurisdictional necessities.
Strategic Takeaways for Litigation
For Patent Holders: Invest in pre-filing claim mapping across all accused products before filing; assess § 101 vulnerability of software-adjacent claims before litigation; avoid over-broad product lists that dilute pleading specificity.
For Accused Infringers: Early Rule 12(b)(6) motions remain powerful, cost-efficient defense tools; technical product differentiation arguments can be embedded in pre-trial motions; retaining large-firm defense counsel early (as ResMed did with Paul Hastings) positions defendants for aggressive early motion practice.
Freedom to Operate (FTO) Analysis for Medical Devices
This case highlights critical IP risks in medical device development, especially for sleep tech. Choose your next step:
📋 Understand This Case’s Impact
Learn about the specific risks and implications from this medical device litigation.
- View all 47 related patents in this technology space
- See which companies are most active in sleep tech patents
- Understand claim construction patterns for respiratory devices
🔍 Check My Product’s Risk
Run a comprehensive FTO analysis for your own medical device or technology.
- Input your product description or technical features
- AI identifies potentially blocking patents, including software
- Get actionable risk assessment report
High Risk Area
Adaptive respiratory therapy systems, connected health software
47 Related Patents
In sleep tech & respiratory care
Design-Around Options
Available for most software/hardware architectures
✅ Key Takeaways
Dismissal without leave to amend signals incurable complaint defects—study the court’s reasoning for future filing strategy in S.D. California.
Search related case law →Multi-product infringement assertions require individualized claim mapping per product, especially for complex medical devices.
Explore precedents →Paul Hastings’ defense approach—early, decisive motion practice—is a replicable model for medical device defendants.
Analyze defense strategies →Individual inventor assertions against large medical device companies remain viable but demand prosecutorial rigor and litigation-ready claim analysis.
Identify similar assertion trends →Monitor U.S. Patent No. 9,639,150 B2 for any continuation applications or related litigation activity.
Track patent family status →Frequently Asked Questions
The case involved U.S. Patent No. 9,639,150 B2 (Application No. 12/172,993), asserted against ResMed’s AirSense 10/11, AirCurve 10/11 device families, and AirView and myAir software platforms.
The court granted ResMed’s motion to dismiss and denied amendment rights, indicating the complaint contained fundamental, incurable legal deficiencies—likely related to pleading sufficiency or patent eligibility under applicable federal standards.
Ready to Strengthen Your Medical Device Patent Strategy?
Join 18,000+ IP professionals using PatSnap Eureka to conduct prior art searches, draft patents, and analyse competitive landscapes with AI-powered precision in the medical device sector.
References
- PACER Case Filing – 3:24-cv-01291
- USPTO Patent US9639150B2
- S.D. California Local Patent Rules
- PatSnap — IP Intelligence Solutions for Law Firms
This article is for informational purposes only and does not constitute legal advice. All case information is drawn from publicly available court records. For platform capabilities, visit PatSnap.